Latest News
Cure SMA Contributes Research Funding to Sixteen SMA Journal Articles in 2013
Originally published on December 30, 2013. Cure SMA is proud to have contributed funding to the research published in the following journal articles in 2013. Cure SMA has invested over […]
Read More ›Cure SMA Funds 25 Research Projects in 2013
Originally published on October 24, 2013. Cure SMA invests in four research areas: Basic Research, Drug Discovery, Clinical Research, and Care Research. Cure SMA has invested over $55 Million in […]
Read More ›Trophos Completes Efficacy Study of Olesoxime in Patients with Spinal Muscular Atrophy
Originally published on November 5, 2013. Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, […]
Read More ›Isis Reports Follow-Up Data From Phase 1 Study In Children With Spinal Muscular Atrophy
Originally published on September 19, 2013. Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular […]
Read More ›Pfizer RG3039 Program for Spinal Muscular Atrophy Reaches Development Milestone
Originally published on September 4, 2013. Reaching the first milestone was triggered by completion of specific program activities and coincides with the successful completion of all transition obligations to Pfizer […]
Read More ›PTC Therapeutics and Roche Announce Spinal Muscular Atrophy Drug Enters First Stage of Clinical Development
Originally published on January 22, 2014. PTC announces that its SMA drug program, partnered with Roche, begins Phase I Safety Trials in healthy, adult volunteers. This brings the total number […]
Read More ›